These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35447464)

  • 41. Essure hysteroscopic sterilization versus interval laparoscopic bilateral tubal ligation: a comparative effectiveness review.
    Ouzounelli M; Reaven NL
    J Minim Invasive Gynecol; 2015; 22(3):342-52. PubMed ID: 25499775
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quality of life after laparoscopic removal of Essure
    Chene G; Cerruto E; Moret S; Lebail-Carval K; Chabert P; Mellier G; Nohuz E; Lamblin G; Clark TJ
    Eur J Obstet Gynecol Reprod Biol X; 2019 Jul; 3():100054. PubMed ID: 31404292
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Two Surgical Techniques for Essure Device Ablation: The Hysteroscopic Way and the Laparoscopic Way by Salpingectomy with Tubal Interstitial Resection.
    Tissot M; Petry S; Lecointre L; Faller E; Baldauf JJ; Akladios C; Boisrame T
    J Minim Invasive Gynecol; 2019; 26(4):603. PubMed ID: 30064007
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysis of tubal patency after essure placement.
    Rodriguez AM; Kilic GS; Vu TP; Kuo YF; Breitkopf D; Snyder RR
    J Minim Invasive Gynecol; 2013; 20(4):468-72. PubMed ID: 23541247
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ASIA (Shoenfeld's syndrome) due to hysteroscopic Essure sterilization.
    Chauhan U; Cassidy B; Cohen Tervaert JW
    Autoimmun Rev; 2021 Dec; 20(12):102979. PubMed ID: 34752966
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pathologic findings in fallopian tubes of women with chronic pelvic pain after Essure placement.
    Rubin A; Chen JF; Veade A; Hagemann IS
    Contraception; 2020 Aug; 102(2):133-136. PubMed ID: 32353358
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and patients' satisfaction after hysteroscopic sterilisation.
    Cabezas-Palacios MN; Jiménez-Caraballo A; Tato-Varela S; Sánchez-Sánchez A; Romero-Díaz C; Carrasco-Gallego A; Zapardiel-Gutiérrez I
    J Obstet Gynaecol; 2018 Apr; 38(3):377-381. PubMed ID: 29046105
    [TBL] [Abstract][Full Text] [Related]  

  • 48. One-step transvaginal three-dimensional hysterosalpingo-foam sonography (3D-HyFoSy) confirmation test for Essure® follow-up: a multicenter study.
    Zizolfi B; Lazzeri L; Franchini M; Di Spiezio Sardo A; Nappi C; Piccione E; Exacoustos C
    Ultrasound Obstet Gynecol; 2018 Jan; 51(1):134-141. PubMed ID: 28067009
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management of long-term and reversible hysteroscopic sterilization: a novel device with nickel-titanium shape memory alloy.
    Xu B; Zhu KA; Xu D; Aili A
    Reprod Biol Endocrinol; 2014 Jul; 12():61. PubMed ID: 24999021
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of Nickel Allergic Reactions to the Essure Micro Insert: Theoretical Risk or Daily Practice?
    Siemons S; Vleugels M; van Eijndhoven H
    J Minim Invasive Gynecol; 2017 Jan; 24(1):140-144. PubMed ID: 27621196
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Occupational exposure to nickel, cobalt, and chromium in the Lithuanian hard metal industry.
    Linauskiene K; Dahlin J; Ezerinskis Z; Isaksson M; Sapolaite J; Malinauskiene L
    Contact Dermatitis; 2021 Apr; 84(4):247-253. PubMed ID: 33277692
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Referrals for complications following hysteroscopic sterilisation: characteristics associated with symptomatic patients after the Essure procedure.
    Sills ES; Dalton MM
    Eur J Contracept Reprod Health Care; 2016 Jun; 21(3):227-33. PubMed ID: 27020693
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tubal sterilization: pregnancy rates after hysteroscopic versus laparoscopic sterilization in France, 2006-2010.
    Fernandez H; Legendre G; Blein C; Lamarsalle L; Panel P
    Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():133-7. PubMed ID: 24993770
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum nickel is associated with craniosynostosis risk: Evidence from humans and mice.
    Xu C; Xu J; Zhang X; Xu S; Liu Q; Weng Z; Gu A
    Environ Int; 2021 Jan; 146():106289. PubMed ID: 33276314
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Essure treatment of hydrosalpinges.
    Hitkari JA; Singh SS; Shapiro HM; Leyland N
    Fertil Steril; 2007 Dec; 88(6):1663-6. PubMed ID: 17490660
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hysteroscopic tubal sterilization: a systematic review of the Essure system.
    Hurskainen R; Hovi SL; Gissler M; Grahn R; Kukkonen-Harjula K; Nord-Saari M; Mäkelä M
    Fertil Steril; 2010 Jun; 94(1):16-9. PubMed ID: 19409549
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diagnostic accuracy of hysterosalpingo-foam-sonography to confirm tubal occlusion after Essure® placement as treatment for hydrosalpinges.
    Dreyer K; Hompes PG; Mijatovic V
    Reprod Biomed Online; 2015 Apr; 30(4):421-5. PubMed ID: 25682307
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Laparoscopic salpingectomy and removal of Essure hysteroscopic sterilisation device: a case series.
    Johal T; Kuruba N; Sule M; Mukhopadhyay S; Raje G
    Eur J Contracept Reprod Health Care; 2018 Jun; 23(3):227-230. PubMed ID: 29842838
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of complications encountered with Essure hysteroscopic sterilization: a systematic review.
    Adelman MR; Dassel MW; Sharp HT
    J Minim Invasive Gynecol; 2014; 21(5):733-43. PubMed ID: 24768959
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Essure(®) for management of hydrosalpinx prior to in vitro fertilisation-a systematic review and pooled analysis.
    Arora P; Arora RS; Cahill D
    BJOG; 2014 Apr; 121(5):527-36. PubMed ID: 24393165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.